Our Pipeline

The Kiniksa pipeline has the potential to treat a spectrum of autoinflammatory & autoimmune diseases.

Program & Mechanism Indication Preclin Early Clinical Mid Clinical Pivotal Mkt Rights
KPL-914 Inflammatory Cardio Disease Mid-Clinical
Worldwide (excl. Middle East and North Africa)
KPL-301 Autoimmune Mid-Clinical
Worldwide
KPL-716 Autoimmune Early-Clinical
Worldwide
KPL-045 Autoimmune Preclinical
Worldwide
KPL-404 Autoimmune Preclinical
Worldwide

About KPL-914

KPL-914 is an approved, subcutaneously-administered, cytokine trap that inhibits the signaling of two soluble cytokines​. There are multiple diseases involving these cytokines where KPL-914 may provide benefit, the first of which is in a rare, inflammatory, cardiovascular disease where there are currently no approved therapies.

KPL-301

Inhibitor of a key growth factor for cells of myeloid lineage

KPL-716

Monoclonal antibody inhibitor of two inflammatory cytokines involved in Th2 response, pruritus, fibrosis and barrier dysfunction

KPL-045

Inhibitor of a T-cell co-stimulatory mechanism important in the function of activated T-memory cells

KPL-404

Inhibitor of a central control node of T-cell-dependent, B-cell-mediated humoral adaptive immunity​